Please login to the form below

Not currently logged in
Email:
Password:

Prevnar

This page shows the latest Prevnar news and features for those working in and with pharma, biotech and healthcare.

Pfizer split still on cards - for tax reasons

Pfizer split still on cards - for tax reasons

cancer therapy Ibrance (palbociclib), arthritis therapy Xeljanz (tofacitinib) and Prevnar pneumonia vaccine family. ... Prevnar grew 16% to top $1.5bn in the quarter, helped by a new indication for use in adults, which added $439m as well as a $40m

Latest news

More from news
Approximately 5 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    This was driven largely by higher-than-expected sales of its pneumonia vaccine, Prevnar, which accounted for more than 11% of its total revenues in the third quarter of 2017.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics